Q1 2026 Jaguar Health Inc Earnings Call Transcript
Key Points
- Jaguar Health Inc (JAGX) reported a significant increase in net revenue, up 816% in Q1 2026 compared to Q1 2025, driven by a transformative out-license agreement.
- The company executed a strategic out-license agreement with Future Pak for Mytesi and Canalevia-CA1, bringing in meaningful nondilutive funding.
- Jaguar Health Inc (JAGX) is focusing on a pivotal stage program for a novel proprietary powder for oral solution formulation of crofelemer, targeting rare intestinal failure indications.
- The company's intestinal failure program represents a blockbuster global market opportunity, with the short bowel syndrome market estimated to reach $8 billion by 2033.
- Initial results from a proof-of-concept study showed crofelemer reduced parenteral support needs by up to 37% in pediatric patients with intestinal failure, demonstrating significant clinical benefits.
- Net revenue for the company's Prescription Products decreased by 62% compared to the fourth quarter of 2025.
- The company reported a net loss attributable to common shareholders of $7.1 million in Q1 2026, despite improvements from the previous year.
- Interest expense increased significantly to approximately $700,000 in Q1 2026 due to new notes, impacting overall financial performance.
- Loss on extinguishment of debt was $600,000 during Q1 2026, indicating financial restructuring challenges.
- The fair value of financial and hybrid instruments decreased, resulting in a loss of $300,000 in Q1 2026, reflecting volatility in financial instruments.
(audio in progress)
Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information and management's current assumptions, expectations and projections about future events. While management believes its assumptions, expectations and projections are reasonable in view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements.
Company's actual results may differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
